Galderma Group AG (GALD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Lucy Codrington from Jefferies maintained a Buy rating on the stock and has a CHF115.00 price target.
Lucy Codrington’s rating is based on several positive indicators for Galderma Group AG. The company’s first-quarter sales exceeded expectations by 2%, largely due to strong performance in the Injectable Aesthetics segment, which saw a 6% sales beat driven by significant growth in Neuromodulators. Additionally, the successful early sales of Sculptra in China, ahead of its planned launch, further contributed to the positive outlook.
Despite some challenges in the Therapeutic Dermatology segment, where legacy business softness led to a 4% decline, the promising $39 million sales of Nemluvio exceeded expectations. The Derm Skincare segment also performed slightly better than anticipated, being 1% ahead of consensus. With the company reiterating its 2025 outlook, these factors collectively suggest a potential uptick in shares, supporting the Buy rating.
In another report released on April 16, Exane BNP Paribas also initiated coverage with a Buy rating on the stock with a CHF100.00 price target.